Source comparison
Muscle Building Peptides 2026 Update: Comparison Table
CJC-1295/Ipamorelin GH secretagogue (pituitary) 15–20% 1.2–1.8kg Injection site irritation, transient water retention Most studied combination with consistent IGF-1 response and favorable safety profile in Phase 2 trials GHRP-2/GHRP-6 Ghrelin receptor agonist
This comparison does not assign a generated winner or score.
- CJC-1295/Ipamorelin
- GH secretagogue (pituitary)
- 15–20%
- 1.2–1.8kg
- Injection site irritation, transient water retention
- Most studied combination with consistent IGF-1 response and favorable safety profile in Phase 2 trials
- GHRP-2/GHRP-6
- Ghrelin receptor agonist
- 18–25%
- 0.8–1.5kg
- Hunger increase, cortisol spike
- High GH response but appetite stimulation limits body recomposition use
- Hexarelin
- GHS-R1a agonist
- 25–30%
- 1.0–1.6kg
- Receptor desensitisation (4–6 weeks), cortisol elevation
- Strongest acute GH pulse but unsustainable for continuous protocols
- BPC-157
- VEGF upregulation, FAK-paxillin modulation
- 0%
- 0kg
- Minimal. Headache in 5–10%
- Recovery peptide with tissue repair effects. No direct anabolic signal
- TB-500
- Actin regulation, cell migration
- Minimal
- Accelerates soft tissue healing. Does not contribute to hypertrophy
- MK-677 (Ibutamoren)
- Ghrelin mimetic (oral)
- 20–35%
- 1.5–2.5kg
- Appetite increase, insulin resistance risk
- Oral bioavailability allows daily dosing but insulin sensitivity monitoring required